Unicycive Therapeutics, INC DEF 14A proxy statements

Unicycive Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 19, 2026, to elect directors and ratify auditor appointment.

Unicycive Therapeutics, Inc. announced that its stockholders approved all proposals at the Annual Meeting held on June 9, 2025, including the election of four directors, ratification of its independent accounting firm, and a reverse stock split.

Unicycive Therapeutics files a second amendment to its proxy statement, updating the beneficial ownership table in advance of its annual meeting on June 9, 2025.

Unicycive Therapeutics announced a change in the time of its 2025 Annual Meeting of Stockholders, while the date and location remain the same.

Unicycive Therapeutics amends its proxy statement to clarify the voting rights of Series A and B Preferred Stock and the quorum requirements for its upcoming annual meeting on June 9, 2025.

Unicycive Therapeutics is holding its annual meeting on June 9, 2025, seeking stockholder approval for key proposals including a reverse stock split to maintain its Nasdaq listing and the election of directors.

Unicycive Therapeutics updates its proxy statement to disclose the engagement of Alliance Advisors as a strategic shareholder advisor and proxy solicitation agent for the upcoming annual meeting.

Unicycive Therapeutics announces its annual stockholder meeting to be held on June 20, 2024, to vote on key proposals including the election of directors, ratification of auditors, approval of a share issuance, an increase in authorized common stock, and an amendment to the equity incentive plan.

Unicycive Therapeutics is holding its annual meeting on June 20, 2024, seeking stockholder approval for director elections, auditor ratification, a Nasdaq compliance proposal, an increase in authorized common stock, and an equity incentive plan amendment.